The American College of Medical Genetics and Genomics, or ACMG, has released a new Evidence-Based Clinical Practice Guideline, or EBG, that makes a "strong recommendation" for the use of NIPS over traditional screening methods for all pregnant individuals with singleton and twin gestations, to screen for fetal trisomy 21, trisomy 18 and trisomy 13 as well as fetal sex chromosome abnormalities. The guideline replaces the 2016 ACMG Position Statement, which recommended that all pregnant individuals have access to NIPS and be made aware of its superior sensitivity for detecting common trisomies, the statement said. An analyst at Stephens has stated that he views the updated recommendations around non-invasive prenatal screening as a positive for Natera (NTRA) and Myriad Genetics (MYGN). Reference Link
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on NTRA:
- Natera: Published study highlights utility of Signatera test
- Natera publishes experience study in twin pregnancies in Prenatal Diagnosis
- Natera price target lowered to $55 from $70 at Credit Suisse
- CareDx, Natera selloffs ahead of CAC meetings overdone, says Raymond James
- Natera price target lowered to $65 from $72 at Baird
